{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:52:20Z","timestamp":1794009140822,"version":"4.8.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Interstitial lung diseases (ILDs) refer to a heterogeneous and complex group of conditions characterized by inflammation, fibrosis, or both, in the interstitium of the lungs. This results in impaired gas exchange, leading to a worsening of respiratory symptoms and a decline in lung function. While the etiology of some ILDs is unclear, most cases can be traced back to factors such as genetic predispositions, environmental exposures (including allergens, toxins, and air pollution), underlying autoimmune diseases, or the use of certain medications. There has been an increase in research and evidence aimed at identifying etiology, understanding epidemiology, improving clinical diagnosis, and developing both pharmacological and non-pharmacological treatments. This review provides a comprehensive overview of the current state of knowledge in the field of interstitial lung diseases.<\/jats:p>","DOI":"10.3389\/fmed.2024.1296890","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T01:11:47Z","timestamp":1713402707000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":113,"title":["Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Malik A.","family":"Althobiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatharth","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos A.","family":"Folarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias","volume":"165","author":"Travis","year":"2002","journal-title":"Am J Respir Crit Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Medicine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults: an official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201402-0373ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease","volume":"189","author":"Maltais","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/thoraxjnl-2019-213620","article-title":"Risk factors for disease progression in idiopathic pulmonary fibrosis","volume":"75","author":"Raghu","year":"2020","journal-title":"Thorax."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur Respir J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.chest.2018.07.038","article-title":"Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis","volume":"155","author":"M\u00e9thot","year":"2019","journal-title":"Chest."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King TE","year":"2014","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/resp.12588","article-title":"Idiopathic interstitial pneumonias with connective tissue diseases features: a review","volume":"21","author":"Cottin","year":"2016","journal-title":"Respirology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/thoraxjnl-2012-202640","article-title":"Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear","volume":"68","author":"Wells","year":"2013","journal-title":"Thorax."},{"key":"B23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1183\/09031936.00152607","article-title":"Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement","volume":"33","author":"Antoniou","year":"2009","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Paolo","year":"2022","journal-title":"Eur Respir J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"210105","DOI":"10.1183\/16000617.0105-2021","article-title":"Sex and gender in interstitial lung diseases","volume":"30","author":"Kawano-Dourado","year":"2021","journal-title":"Eur Respir Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"170042","DOI":"10.1183\/16000617.0042-2017","article-title":"New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis","volume":"26","author":"Torre","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fmed.2018.00148","article-title":"The management of patients with idiopathic pulmonary fibrosis","volume":"5","author":"Spagnolo","year":"2018","journal-title":"Front Med."},{"key":"B29","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B30","first-page":"333","article-title":"Lupus pernio de la face","volume":"10","author":"Besnier","year":"1889","journal-title":"Ann Dermatol Syph."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012953","article-title":"Continuous glucose monitoring systems for the diagnosis of cystic fibrosis-related diabetes","author":"Ahmed","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1399-0039.1994.tb02331.x","article-title":"Molecular genetic studies of HLA class II alleles in sarcoidosis","volume":"43","author":"Ishihara","year":"1994","journal-title":"Tissue Antigens."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.rmed.2019.03.012","article-title":"Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis","volume":"152","author":"Judson","year":"2019","journal-title":"Respir Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MOH.0000000000000301","article-title":"Mechanism of granuloma formation in sarcoidosis","volume":"24","author":"Sakthivel","year":"2017","journal-title":"Curr Opin Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/jomfp.jomfp_373_21","article-title":"Premika, Nachiammai N. Sarcoidosis - a review article","volume":"26","author":"Sreeja","year":"2022","journal-title":"J Oral Maxillofac Pathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"537382","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1513\/AnnalsATS.202204-328OC","article-title":"Heterogeneity of lung function phenotypes in sarcoidosis: role of race and sex differences","volume":"20","author":"Sharp","year":"2023","journal-title":"Ann Am Thorac Soc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1378\/chest.92.3.488","article-title":"Association of HLA-DR with sarcoidosis. Correlation with clinical course","volume":"92","author":"Abe","year":"1987","journal-title":"Chest."},{"key":"B41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4187\/respcare.02101","article-title":"Efficacy and safety of conventional transbronchial needle aspiration in sarcoidosis: a systematic review and meta-analysis","volume":"58","author":"Agarwal","year":"2013","journal-title":"Respir Care."},{"key":"B42","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000490192","article-title":"A randomized trial evaluating the effect of 10 versus 20 revolutions inside the lymph node on the diagnostic yield of EBUS-TBNA in subjects with sarcoidosis","volume":"96","author":"Dhooria","year":"2018","journal-title":"Respiration."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5334\/aogh.2414","article-title":"Interstitial lung diseases in developing countries","volume":"85","author":"Rivera-Ortega","year":"2019","journal-title":"Ann Glob Health."},{"key":"B44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1378\/chest.10-0804","article-title":"The nonspecific pulmonary function test: longitudinal follow-up and outcomes","volume":"139","author":"Iyer","year":"2011","journal-title":"Chest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1753465810379801","article-title":"The pathogenesis of idiopathic pulmonary fibrosis","volume":"4","author":"Coward","year":"2010","journal-title":"Ther Adv Respir Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.202109-2065OC","article-title":"Neighborhood-level disadvantage impacts on patients with fibrotic interstitial lung disease","volume":"205","author":"Goobie","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.20.558301v1","article-title":"Peripheral blood single-cell sequencing uncovers common and specific immune aberrations in fibrotic lung diseases","author":"Zhao","year":"2023","journal-title":"bioRxiv"},{"key":"B49","doi-asserted-by":"publisher","first-page":"687397","DOI":"10.3389\/fimmu.2021.687397","article-title":"Commonalities between ARDS, pulmonary fibrosis and COVID-19: the potential of autotaxin as a therapeutic target","volume":"12","author":"Ntatsoulis","year":"2021","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"110289","DOI":"10.1016\/j.cbi.2022.110289","article-title":"Transforming growth factor-\u03b2 signaling: from tissue fibrosis to therapeutic opportunities","volume":"369","author":"Ren","year":"2023","journal-title":"Chem Biol Interact."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.29.23289296","article-title":"Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis","author":"Unterman","year":"2023","journal-title":"medRxiv."},{"key":"B52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1164\/rccm.200812-1966OC","article-title":"Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)\u2013lung study","volume":"180","author":"Lederer","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.etp.2005.05.010","article-title":"Analysis of complex mixtures\u2013cigarette smoke","volume":"57","author":"Borgerding","year":"2005","journal-title":"Exp Toxicol Pathol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Murray","year":"2020","journal-title":"Lancet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/tobaccocontrol-2021-056535","article-title":"Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action","volume":"31","author":"Xiaochen","year":"2022","journal-title":"Tob Control."},{"key":"B57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.chest.2017.11.023","article-title":"Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases","volume":"154","author":"Kumar","year":"2018","journal-title":"Chest."},{"key":"B58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ccm.2011.11.004","article-title":"Smoking-related interstitial lung diseases","volume":"33","author":"Vassallo","year":"2012","journal-title":"Clin Chest Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0002-9343(65)90206-8","article-title":"Desquamative interstitial pneumonia","volume":"39","author":"Liebow","year":"1965","journal-title":"Am J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"190181","DOI":"10.1183\/16000617.0181-2019","article-title":"Desquamative interstitial pneumonia: a systematic review of its features and outcomes","volume":"29","author":"Hellemons","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1056\/NEJM197410102911503","article-title":"Pathologic changes in the peripheral airways of young cigarette smokers","volume":"291","author":"Niewoehner","year":"1974","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.chest.2018.01.015","article-title":"Air pollution exposure is associated with lower lung function, but not changes in lung function, in patients with idiopathic pulmonary fibrosis","volume":"154","author":"Johannson","year":"2018","journal-title":"Chest."},{"key":"B63","volume-title":"Ambient (outdoor) Air Pollution.","year":"2022"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1183\/09031936.00122213","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure","volume":"43","author":"Johannson","year":"2014","journal-title":"Eur Respir J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1378\/chest.14-1299","article-title":"Air pollution exposure: a novel environmental risk factor for interstitial lung disease?","volume":"147","author":"Johannson","year":"2015","journal-title":"Chest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1700397","DOI":"10.1183\/13993003.00397-2017","article-title":"The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy","volume":"51","author":"Conti","year":"2018","journal-title":"Eur Respir J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1801563","DOI":"10.1183\/13993003.01563-2018","article-title":"Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1164\/rccm.202003-0836PP","article-title":"Air pollution and interstitial lung diseases: defining epigenomic effects","volume":"202","author":"Goobie","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/thoraxjnl-2015-208148","article-title":"Interstitial lung disease: time to rethink the snapshot diagnosis?","volume":"71","author":"Danielle","year":"2016","journal-title":"Thorax."},{"key":"B70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000329891","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors","volume":"83","author":"Simon-Blancal","year":"2012","journal-title":"Respiration."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1164\/rccm.201904-0717ST","article-title":"The occupational burden of nonmalignant respiratory diseases. An official american thoracic society and european respiratory society statement","volume":"199","author":"Blanc","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/ijerph15051000","article-title":"Global asbestos disaster","volume":"15","author":"Furuya","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"B73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4104\/pcrj.2013.00055","article-title":"Pneumoconiosis","volume":"22","author":"Cullinan","year":"2013","journal-title":"Prim Care Respir J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1056\/NEJMcibr1811639","article-title":"Revealing the secrets of idiopathic pulmonary fibrosis","volume":"380","author":"Albert","year":"2019","journal-title":"N Engl J Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41467-023-37193-6","article-title":"Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts","volume":"14","author":"Adegunsoye","year":"2023","journal-title":"Nat Commun."},{"key":"B76","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0701009104","article-title":"Adult-onset pulmonary fibrosis caused by mutations in telomerase","volume":"104","author":"Tsakiri","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/jmg.2008.057356","article-title":"A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis","volume":"45","author":"Mushiroda","year":"2008","journal-title":"J Med Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e10680","DOI":"10.1371\/journal.pone.0010680","article-title":"Leon A, Cronkhite JT, Katzenstein A-LA, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations","volume":"5","author":"Diaz","year":"2010","journal-title":"PLoS ONE."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.rmed.2011.08.022","article-title":"Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Garc\u00eda-Sancho","year":"2011","journal-title":"Respir Med."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.1432","article-title":"Telephone follow-up, standardized to the initiation of biologic therapy of patients with rheumatoid arthritis (RA) in a specific unit of biologic therapy. Pilot study","author":"Cano-Garcia","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ccm.2021.04.011","article-title":"Interstitial lung diseases and the impact of gender","volume":"42","author":"Karampitsakos","year":"2021","journal-title":"Clin Chest Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"00259","DOI":"10.1183\/23120541.00259-2018","article-title":"Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study","volume":"5","author":"Rittig","year":"2019","journal-title":"ERJ Open Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1378\/chest.15-0530","article-title":"Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline","volume":"149","author":"Salisbury","year":"2016","journal-title":"Chest."},{"key":"B87","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccm.2020.08.015","article-title":"Occupational contributions to interstitial lung disease","volume":"41","author":"Reynolds","year":"2020","journal-title":"Clin Chest Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4415\/ANN_16_02_12","article-title":"Sex-based differences in autoimmune diseases","volume":"52","author":"Ortona","year":"2016","journal-title":"Ann Ist Super Sanita."},{"key":"B89","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2019.7194","article-title":"Clinical advances in sex-and gender-informed medicine to improve the health of all: a review","volume":"180","author":"Bartz","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccm.2021.04.012","article-title":"Gender differences in critical illness and critical care research","volume":"42","author":"Lat","year":"2021","journal-title":"Clin Chest Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/medsci6040110","article-title":"Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes","volume":"6","author":"Sauleda","year":"2018","journal-title":"Med Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"GBD","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"751181","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in global prevalence of interstitial lung disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","article-title":"Epidemiology and real-life experience in progressive pulmonary fibrosis","volume":"28","author":"Valenzuela","year":"2022","journal-title":"Curr Opin Pulm Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"Eur Respir J"},{"key":"B96","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J."},{"key":"B97","volume-title":"The Battle for Breath: The Impact of Lung Disease in the UK","author":"Foundation","year":"2016"},{"key":"B98","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/1817-1737.105717","article-title":"Interstitial lung diseases in Saudi Arabia: a single-center study","volume":"8","author":"Alhamad","year":"2013","journal-title":"Ann Thorac Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"h2072","DOI":"10.1136\/bmj.h2072","article-title":"The diagnosis and management of interstitial lung diseases","volume":"350","author":"Wallis","year":"2015","journal-title":"BMJ"},{"key":"B100","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7861\/clinmedicine.17-2-146","article-title":"Update in diagnosis and management of interstitial lung disease","volume":"17","author":"Mikolasch","year":"2017","journal-title":"Clin Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"220003","DOI":"10.1183\/16000617.0003-2022","article-title":"Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives","volume":"31","author":"Vincent","year":"2022","journal-title":"Eur Respir Rev."},{"key":"B102","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/24745332.2017.1359056","article-title":"Evaluation of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society position statement","volume":"1","author":"Johannson","year":"2017","journal-title":"Can J Respir Crit Care Sleep Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1174443","DOI":"10.3389\/fmed.2023.1174443","article-title":"Novel diagnostic techniques in interstitial lung disease","volume":"10","author":"Glenn","year":"2023","journal-title":"Front Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"9026171","DOI":"10.1155\/2020\/9026171","article-title":"The impact of multidisciplinary discussion (MDD) in the diagnosis and management of fibrotic interstitial lung diseases","volume":"2020","author":"Ageely","year":"2020","journal-title":"Can Respir J"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official american thoracic society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/jan.12587","article-title":"Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis","volume":"71","author":"Duck","year":"2015","journal-title":"J Adv Nurs."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1801587","DOI":"10.1183\/13993003.01587-2018","article-title":"The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study","volume":"53","author":"Torrisi","year":"2019","journal-title":"Eur Respir J"},{"key":"B108","doi-asserted-by":"publisher","first-page":"160027","DOI":"10.1183\/16000617.0027-2016","article-title":"Comorbidities in interstitial lung diseases","volume":"26","author":"Margaritopoulos","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.chest.2020.04.019","article-title":"Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic","volume":"158","author":"Wong","year":"2020","journal-title":"Chest."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-1076-0","article-title":"Risk factors for diagnostic delay in idiopathic pulmonary fibrosis","volume":"20","author":"Hoyer","year":"2019","journal-title":"Respir Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"00124","DOI":"10.1183\/23120541.00124-2019","article-title":"Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey","volume":"5","author":"Moor","year":"2019","journal-title":"ERJ Open Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1190235","DOI":"10.3389\/fimmu.2023.1190235","article-title":"Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review","volume":"14","author":"Bintalib","year":"2023","journal-title":"Front Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","article-title":"Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study","volume":"8","author":"Troy","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3872790\/v1","author":"Bian","year":"2024","journal-title":"Assessment of a Randomized Controlled Trial on the Safety of Pre-placing Bronchial Balloons in Transbronchial Lung Cryobiopsy for Diagnosing Interstitial Lung Disease"},{"key":"B115","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4103\/lungindia.lungindia_275_20","article-title":"Management of interstitial lung diseases: a consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP)","volume":"37","author":"Singh","year":"2020","journal-title":"Lung India."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin."},{"key":"B117","doi-asserted-by":"publisher","first-page":"180074","DOI":"10.1183\/16000617.0074-2018","article-title":"Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence","volume":"27","author":"Richeldi","year":"2018","journal-title":"Eur Respir Rev"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jpainsymman.2019.12.364","article-title":"Idiopathic pulmonary fibrosis: a review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life","volume":"59","author":"Rozenberg","year":"2020","journal-title":"J Pain Symptom Manage."},{"key":"B119","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/annrheumdis-2013-eular.1523","article-title":"Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (scleroderma lung study II): rationale, design, methods, baseline characteristics and patient disposition","author":"Khanna","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003536.pub2","article-title":"Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis","author":"Paramothayan","year":"","journal-title":"Cochrane Database Syst Rev"},{"key":"B123","first-page":"5","volume-title":"Interstitial Lung Disease: Time to Rethink the Snapshot Diagnosis?","author":"Antin-Ozerkis","year":"2016"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-020-1296-3","article-title":"Progression of fibrosing interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: a review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Resp Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration."},{"key":"B131","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J."},{"key":"B132","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation","volume":"188","author":"Spruit","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1900647","DOI":"10.1183\/13993003.00647-2019","article-title":"Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes","volume":"55","author":"Guler","year":"2020","journal-title":"Eur Respir J"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"S1708","DOI":"10.21037\/jtd.2019.05.09","article-title":"Indications for lung transplant referral and listing","volume":"11","author":"Shweish","year":"2019","journal-title":"J Thorac Dis."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006322.pub4","article-title":"Pulmonary rehabilitation for interstitial lung disease","author":"Dowman","year":"","journal-title":"Cochrane Database Syst Rev"},{"key":"B138","first-page":"663","article-title":"American Thoracic Society. Medical section of the American Lung Association pulmonary rehabilitation","volume":"124","author":"Hodgkin","year":"1981","journal-title":"Am Rev Respir Dis."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/1060028019862497","article-title":"Management of idiopathic pulmonary fibrosis","volume":"53","author":"Pleasants","year":"2019","journal-title":"Ann Pharmacother."},{"key":"B140","doi-asserted-by":"publisher","first-page":"744102","DOI":"10.3389\/fresc.2021.744102","article-title":"Exercise-based pulmonary rehabilitation for interstitial lung diseases: a review of components, prescription, efficacy, and safety","volume":"2","author":"Mendes","year":"2021","journal-title":"Front Rehabil Sci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/00039896.1975.10666650","article-title":"Lung function consequences of dust exposure in asbestos cement manufacturing plants","volume":"30","author":"Weill","year":"1975","journal-title":"Arch Environ Health"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ajt.14081","article-title":"Effect of lung transplantation on health-related quality of life in the era of the lung allocation score: a US prospective cohort study","volume":"17","author":"Singer","year":"2017","journal-title":"Am J Transpl."},{"key":"B143","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/ajt.15677","article-title":"OPTN\/SRTR 2018 annual data report: lung","volume":"20","author":"Valapour","year":"2020","journal-title":"Am J Transplant"},{"key":"B144","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/bmjspcare-2012-000215","article-title":"How to design and implement palliative care public health programmes: foundation measures","volume":"3","author":"G\u00f3mez-Batiste","year":"2013","journal-title":"BMJ Support Palliat Care."},{"key":"B145","volume-title":"Palliative Care","year":"2020"},{"key":"B146","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.200605-587ST","article-title":"An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses","volume":"177","author":"Lanken","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/1479972312471549","article-title":"Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival","volume":"10","author":"Irwin","year":"2013","journal-title":"Chron Respir Dis."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12904-017-0220-1","article-title":"The provision of generalist and specialist palliative care for patients with non-malignant respiratory disease in the North and Republic of Ireland: a qualitative study","volume":"17","author":"Veigh","year":"2018","journal-title":"BMC Palliat Care."},{"key":"B149","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/bmjspcare-2016-001119","article-title":"Commissioning of specialist palliative care services in England","volume":"8","author":"Lancaster","year":"2018","journal-title":"BMJ Support Palliat Care."},{"key":"B150","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.hrtlng.2016.10.002","article-title":"The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers","volume":"46","author":"Lindell","year":"2017","journal-title":"Heart Lung."},{"key":"B151","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bmjspcare-2018-001575","article-title":"Barriers to specialist palliative care in interstitial lung disease: a systematic review","volume":"9","author":"Kim","year":"2019","journal-title":"BMJ Support Palliat Care."},{"key":"B152","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1049909117713990","article-title":"Access to palliative care for patients undergoing mechanical ventilation with idiopathic pulmonary fibrosis in the United States","volume":"35","author":"Rush","year":"2018","journal-title":"Am J Hospice Palliat Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS ONE."},{"key":"B154","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The impact of lung cancer on survival of idiopathic pulmonary fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest."},{"key":"B155","doi-asserted-by":"publisher","first-page":"190158","DOI":"10.1183\/16000617.0158-2019","article-title":"Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review","volume":"29","author":"Khor","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B156","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Resp Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.20.558301","article-title":"Peripheral blood single-cell sequencing uncovers common and specific immune aberrations in fibrotic lung diseases","author":"Zhao","year":"2023","journal-title":"bioRxiv"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"Du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/00063198-200009000-00003","article-title":"The role of pulmonary function testing in pulmonary fibrosis","volume":"6","author":"Flaherty","year":"2000","journal-title":"Curr Opin Pulm Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1378\/chest.103.6.1808","article-title":"Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases","volume":"103","author":"Kondoh","year":"1993","journal-title":"Chest."},{"key":"B163","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","article-title":"Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature","volume":"11","author":"Manfredi","year":"2019","journal-title":"J Thorac Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J."},{"key":"B166","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","article-title":"The burden of progressive fibrosing interstitial lung disease: a DELPHI approach","volume":"37","author":"Wuyts","year":"2020","journal-title":"Adv Ther."},{"key":"B167","doi-asserted-by":"publisher","first-page":"00441","DOI":"10.1183\/23120541.00441-2021","article-title":"Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review","volume":"7","author":"Althobiani","year":"2021","journal-title":"ERJ Open Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"e51507","DOI":"10.2196\/51507","article-title":"Evaluating a remote monitoring program for respiratory diseases: prospective observational study","volume":"7","author":"Althobiani","year":"2023","journal-title":"JMIR Form Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1296890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T01:11:53Z","timestamp":1713402713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1296890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":168,"alternative-id":["10.3389\/fmed.2024.1296890"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1296890","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"article-number":"1296890"}}